

Article type : Research Article

Date Received :19/07/2021

Date Accepted : 11/08/2021

Date published : 01/09/2021



: www.minarjournal.com

<http://dx.doi.org/10.47832/2717-8234.3-3.3>



REVIEW OF ACINETOBACTER BAUMANNII: TAXONOMY, EPIDEMIOLOGY, PATHOGENICITY, AND ANTIMICROBIAL RESISTANCE

Khalida J. IBRAHEEM¹ & Mohammed S. BAQER²

Abstract

Genus Acinetobacter are wide spread in nature , and there are at least 25 different types of them .In the medical field Acinetobacter baumannii is one of the most important species of this genus. It is an opportunistic pathogen and have many virulence factors that make the bacteria capable of causing many hospital-acquired diseases leads to nosocomial outbreak attendant with rise in death rates . This bacteria has the ability to be resistant to many antibiotics and the emergence of high levels of multi-drug resistance A. baumannii has made it priority health issue and is considered a serious threat to health care facilities , public health and the elderly which requires a tremendous effort to stop this escalation.

Keywords: Acinetobacter Baumannii, Multi-Drug Resistance, Hospital-Acquired Infections.

¹ Mustansiriyah University, Iraq, Khalida.edbs@uomustansiriyah.edu.iq, <https://orcid.org/0000-0003-3473-0995>

² Mustansiriyah University, Iraq, Mohammed79@uomustansiriyah.edu.iq, <https://orcid.org/0000-0003-1502-5756>

1.Introduction

The genus *Acinetobacter* was first isolated from soil in 1911 by scientist Beijerinck who called *Micrococcus calcoaceticus* [1,2]. During the 1940s, the last century it was referred to known as *Acinetobacter* [3]. The genus *Acinetobacter* includes species which are gram-negative coccobacilli, non-motile, strictly aerobic and non-oxidase production, while catalase is produced [4]. On usual laboratory media, it can grow easily and found in humid environments including ponds, waste water, moist soil, water treatment plant, fish farms and sea water [5]. *Acinetobacter* are wide spread in nature and there are at least 25 different types of them [6]. During the past two decades, clinical importance of *A. baumannii* isolates were increased due to the injuries caused among the wounded American soldiers during the war in Iraq and Afghanistan and high ability to acquire resistance to all antibiotics which are currently used, as well as their ability to stay for a long time in the hospital environment which lead to their rapid spread and infection outbreaks [7,8]. Also, *A. baumannii* is responsible for many hospital acquired infections including Pneumonia were associated with the artificial respiration system in patients were confined to hospital intensive care units (ICUs). It can infect the skin, wounds, the respiratory system and digestive system in human [9,10]. *A. baumannii* is characterized by having many virulence factors that contribute to its pathogenicity [11]. This review aimed to focus on the role of *Acinetobacter baumannii* which is considered one of the most important pathogens that cause infectious disease in hospital around the world and multi-drug resistant that made it a priority health issue.

Acinetobacte baumannii

Medically, it is the most important species of the genus *Acinetobacter*. The species was first isolated from soil and water in (1968) by scientist Baumann, as well as from food samples such as meat and vegetables. It was also isolated from various human pathological samples such as blood, sputum, pleural fluid and urine [12]. *A. baumannii* appears as gram-negative coccobacilli are non-motile, aerobic, opportunistic pathogens that mainly attack hospitalized patients they have the ability to resist and survive for a long time throughout hospitals enhances their ability to spread [13]. Biochemical characteristics of *Acinetobacter baumannii* shown in table (1). This type can survive for a long time in dry conditions, for example it lasts 7 days on dry washed clothes, 6 days on dry filter paper, 3 days on Formica, 7 days on glass and more than 25 days on cotton. It has the ability to grow at a temperature of 44°C and this is what distinguishes it from other species [14].

Table 1 : Biochemical characteristics of *Acinetobacter baumannii*

Tests	Results
Morphology	Coccobacilli
Motility	Non motile
Hemolysis	-ve
Growth at 37°C, 44°C	+ve
Production of Oxidase	-ve
Production of Catalase	+ve
Utilization of citrate	+ve
Hydrolysis of gelatin	-ve
Oxidative-Fermentative(Glucose, Dextrose)	+ve
Arginine	+ve
Malonate	+ve
Production of urease	-ve
Reduction of nitrate	-ve
Production of Indole	-ve
Fermentation of lactose	-ve

(-ve : Negative , +ve Positive)

Current Taxonomy State

According to Bergey's Manual of Systematic Bacteriology were categorized the Acinetobacter genus with the Neisseriaceae family [15], and one species Acinetobacter calcoaceticus. The names of the species have persisted great taxonomic modifications over the years because of the superior knowledge of molecular strategies of the genetic makeup of this set of pathogens [16]. Recent classification of Acinetobacter which has accepted by bacterial taxonomists is shown in table 2 [17,18].

Table 2 :Recent classification of Acinetobacter baumannii

Classification	
Domain	Bacteria
Phylum	Proteobacteria
Class	Gammaproteobacteria
Order	Pseudomonadales
Family	Moraxellaceae
Genus	Acinetobacter
Species	Acinetobacter baumannii

Epidemiology of Acinetobacter baumannii

The epidemiology of Acinetobacter baumannii is a wide spread which includes infection related to wars, tropical environments, and hospital – acquired infections [19]. It can inhabit soil and water, and other probably reservoirs include lice and food animal [20]. In human, high colonization rates of the skin, throat, wounds, respiratory tract and gastrointestinal tracts of various degree of importance documented in numerous outbreaks [21,22]. In particular outbreaks among patients in the intensive care unit (ICU). In addition, many reports have been indicating cause of outbreaks and nosocomial infections which involve ventilator - associated pneumoniae, meningitis, septicemia, bacteremia, urinary tract infections and endocarditis [23,24]. Most epidemiological studies have been described the prevalence of infection with multi-drug resistance A. baumannii more than 21% of all hospital infection in various regions of the world, including North America, China, Brazil, Japan and Europe [25]. Several cases have been reported from hospitals in the middle East such as United Arab Emirates, Saudi Arabia, Bahrain and Lebanon, which indicated prevalence of infection by A. baumannii from 19.1% in 2006 to 90% in 2015 [26,27]. Community acquired pneumonia infection have been reported in Asia and Australia especially during the wet season [28,29]. It is not known what causes a high rates of infection with Acinetobacter in a particular geographical area, however this may be due to the variation in temperature and humidity that affect the colonized bacteria [30].

Pathogenicity

A. baumannii is an opportunistic bacterium that has attracted the attention of specialists may be due to its high ability to develop resistance against many antibiotics (Multiple Drug Resistance (MDR)) and it has the potential to acquire genetic material from different strains as well as its biofilm formation and its great ability to adhere to surface [31]. The cause of pathogenicity of A. baumannii is due to its possession of many virulence factors (Figure 1) including (curli fibers, cytotoxic, necrotizing factor, siderophores and aerobactin), in addition to its production of colicin (v), gelatinase, capsule and possession of polysaccharides and the formation of pellicle assay. Also it produces some types of enzymes, including lipolytic enzyme (lipase) and proteolytic enzyme (protease) [32]. Diseases caused by A. baumannii are wide spread and in different areas of the human body with varying severity among the infected. These infections include: pneumonia, endocarditis, meningitis, wound and burn injuries, peritonitis, osteomyelitis, arthritis and bacteremia [33,34]. It can also colonize the skin, the nervous system and the eyes, and cause soft tissue infections [35,36] and poses a major risk to hospitalized patients especially those in the Intensive Care Unit (ICU). Those who are

immunocompromised and spent long time in the hospital and these are exposed to infection with bacteria through hospital equipment or through the care workers by direct contact with the infected patient, and this bacteria is contaminated in different parts of the hospital environment, it was found on curtains, throat examination blades, door handles, wipers, keys, patient lift equipment, as well as a medical equipment. They need to pay attention to disinfecting common equipment, especially catheter and respiratory equipment [37,38].




Figure 1:Virulence factor of *Acinetobacter baumannii*

Resistance of *A. baumannii* to antibiotics

A. baumannii have spread throughout the world due to their ability to survive in various environmental conditions and to acquire new genetic factors as a result of: first – mobile genetic elements such as transferable plasmid and integrons. Second – the inherited modification of the autonomous genes by mutations that change the target of the antagonists, which in turn change the self – resistance [39,40]. The presence of such motile genetic elements are concern and acquisition of genes can trigger drastic changes in resistance. Additionally, the ability of *A. baumannii* to confer on plasmids carrying anti – resistance traits are likely to spread among other types of bacteria [41,42]. The bacteria exhibit self – resistance to various antigens due to the decrease of the permeability in the outer membrane and flow pumps. The bacteria have become resistance to all commonly antibiotics including, B-lactams, Quinolones, polymyxins, Aminoglycosides, Tetracyclines, Chloramphenicol and Glycylcyclines [43,44]. The resistance of *A. baumannii* to beta lactams includes several mechanisms (A): Enzymatic mechanisms or the production of antigen degradation enzymes. The main mechanisms in resistance to beta– lactam lies in their composition of broad spectrum beta lactamases, which are encoded by genes that carried on a plasmid or chromosome. The AMPC – B – lactamases is one of the chromosomal enzymes that degrade broad – spectrum cephalosporins, except for cefepime [45,46]. AS well as the enzyme Oxacillinases (OXA), which are characterized by their effectiveness of analyzing anti-carbapenems. As for the enzymes containing minerals, they degrade all B- lactams except for Aztreonam which are often encoded by mobile genetic elements that can pass easily between bacteria [47]. (B): Non – enzymatic mechanisms including changing the permeability of the membrane either by losing or decreasing outer membrane proteins (OMPs), or by increasing the flow pumps which leads to prevent the entry of the antagonist or enhance its expulsion to the outside [48]. The sequences of penicillin binding proteins (PBPs) were varied, as changes occur in the expression levels of normal PBPs. Studies have indicated that there are several differences in the expression pattern of the binding proteins between *A. baumannii* susceptible bacteria and anti – carbapenem resistant and that decrease in antagonist affinity which is associated with increased expression of these proteins [49]. *A. baumannii* resists Quinolones by modulating the

antibody binding site where mutation occur in genes encoding the DNA gyrase or one of the targeted topoisomerases and the bacteria also have flow pumps that cat on the extracellular antagonist tunnel [50] . As for the resistance of *A. baumannii* to aminoglycoside it can be by changing the flow pumps or by expressing the modulating enzymes , especially Acetyltransferases , Nucleotidyl transferases and phosphotransferases . To produce these enzymes , the encode chromosomal or plasmid genes or paired with integrons and jumpers genes [51,52] . These enzymes modify the hydroxyl or amine group present within these antibiotics and thus reduce the affinity for the target site . Bacteria possess the gene responsible for the 16s rRNA methylation that prevents significant resistance to most Aminoglycosides such as Amikacin , Tobramycin and Gentamicin [53,54] while the mechanisms of bacterial resistance to Tetracycline are modulated the target site on the ribosomal subunit (30s), due to presence of the gene which is carried on the conjugated plasmide which were encoded for the protein that provides protection of the ribosomal subunit of the antibiotic , as well as the possession of a gene that encodes flow systems for this antibiotic [55,56] . As for the mechanism of resistance to polymyxins , it reduced the net negative charge of the outer membrane of the bacteria and thus reduced the affinity between the antibiotic and the surface at the bacteria , as indicated by [57,58] , as for the mechanism of action of polymyxins is by stable electrical interactions between the positive charges of polymyxins groups and the negatively charged phosphate groups on Lipid A in lipopolysaccharide (LPS) and resistance can occur as a result in inhibition of certain genes responsible for the biosynthesis of the membrane of lipid A or the elimination completely [59]. Also [60]was indicated that alterations to lipid A with the introduction of phosphor-ethanolamine were presented in all isolates of *A. baumannii* anti-colistin resistance.

Conclusion

Acinetobacter baumannii was considered one of the most important pathogen that cause infectious diseases in hospitals around the world . The emergence of high levels of multi-drug resistant *A. baumannii* made them a priority health issue, especially in hospital and nursing homes for children and the elderly which are requires further research and development to discover new antibiotics to reduce deaths from resistant infections around the world . It is also necessary to improve programs to prevent and limit the spread of infection with this pathogens in hospitals.

References

- L. Dijkshoorn , The diversity of the genus *Acinetobacter* . I Gerischer , U. (Ed.), *Acinetobacter Molecular Biology* (2008) Caister Academic Press , ISBN.
- H.J. Doughari , P.A. Ndakidemi , I.S. Human, S. Benade , The ecology , biology and Pathogenesis of *Acinetobacter* spp .: an overview *Microbes Environ* (2011) , 26, 101-112
- L.S. Munoz-Price , R.A. Weinstein, *Acinetobacter* infection. *N. Engl. J. Med.* (2008) ,358, 1271–1281.
- B. Kurcik – Trajkovska , *Acinetobacter* spp. - a serious enemy threatening hospitals worldwide. *Maced. J. Med. Sci.* (2009) , 2, 157–162.
- A. Towner, The genus *Acinetobacter*. *The Prokaryotes*. Springer,(2006)pp. 746–758.M. Joly-Guillou , impact and pathogenicity of *Acinetobacter* *Clinical Microbiology and Infection*.(2005) , 11: 868-73.
- A. Boulanger, T. Nass , N. Fortineau , S. Figueiredo, and P. Nordmann , NDM -1-producing *Acinetobacter baumannii* from algeria . *Antimicrobial Agents and Chemotherapy* (2012) , 56 : 2214-2215.
- H. Aoife , D. Michael , F. Audrey , and Roy , Sleator . *Acinetobacter baumannii* an emerging opportunistic pathogen. *Virulence* (2012) , 3 : 243–250 .
- MZ .Chen , PR. Hsueh , LN. Lee , et al. Severe community - acquired pneumonia due to *Acinetobacter baumannii*. *Chest* (2001): 120:107.
- MC. Albrecht , ME. Griffith , CK. Murray , et al. Impact of *Acinetobacter* infection on the mortality. of burn patients. *J Am Coll Surg* (2006), 203:546.
- M. Federico , E. Ruiz , S. Mercedes , T. Eva , C. Esther , and R. Antonio , Crystal Structure of hcp from *Acinetobacter baumannii* : A component of type VI secretion system . *PLoS One*, (2015) , 16;10 :e 0129691.
- L. King , E. Swiatlo , A. Swiatlo , and L. McDaniel , Serum resistance and Bio Information in clinical isolates of *Acinetobacter baumannii* . *FEMS Immunology and Medical Microbiology* (2009) ,55 : 414–421.
- Y. Anton , S. Harald , and L. David , *Acinetobacter baumannii* : Emergence of a Successful Pathogen. *Journal of Clinical Microbiology* (2008) , 21, :538–582.
- G. Brooks , J. Butel, and S. Mors, Jawtz , Melnck and Adelberg *medical microbiology*. (2007) , 24th ed. McGraw-Hill. New.
- E. Juni, 1984. Genus III. *Acinetobacter* Brisou et Prévot 1954, p. 303-307. In N. R. Krieg, and J. G. Holt (ed.), *Bergey's manual of systematic bacteriology*, vol. 1. The Williams & Wilkins Co., Baltimore.
- P. Kämpfer, I. Tjernberg, and J. Ursing. Numerical classification and identification of *Acinetobacter* genomic species. *J. Appl. Bacteriol* (1993), 75:259- 268.

- N. Gordon , D. and Wareham , "Multidrug - resistant *Acinetobacter baumannii*: Mechanisms of virulence and resistance . " *International Journal of Antimicrobial Agents*(2010) , 35 : 219-226.
- J. Jung, W. Park, *Acinetobacter* species as model microorganisms in environmental microbiology: current state and perspectives . *Appl. Microbiol. Biotechnol.* .(2015) , 99, 2533-2548.
- DE. Berg, RC. Hershov, CA. Ramirez, RA. Weinstein. Control of nosocomial infections in an intensive care unit in Guatemala City. *Clin Infect Dis* (1995); 21:588.
- ET. Houang , YW. Chu , CM. Leung. et al . Epidemiology and infection control implications of *Acinetobacter* spp. in Hong Kong, *J Clin Microbiol* (2001): 39:228.
- AM. –Richards , Y. Abu Kwaik,RJ. Lamont . Code blue : *Acinetobacter baumannii* , a nosocomial pathogen with a role in the oral cavity , *Mol Oral Microbiol* (2015): 30:2.
- FA. Scannapieco ,RB. Bush , S. Paju . Associations between periodontal disease and risk for nosocomial bacterial pneumonia and chronic obstructive pulmonary disease. A systematic review. *Ann Periodontol*(2003): 8:54.
- H. Wisplinghoff ,MB. Edmond, MA. Pfaller, et al. Nosocomial bloodstream infections caused by *Acinetobacter* species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. *Clin Infect Dis* (2000); 31:690.
- H. Seifert, A. Strate, G. Pulverer. Nosocomial bacteremia due to *Acinetobacter baumannii*. Clinical features, epidemiology, and predictors of mortality. *Medicine (Baltimore)*, (1995); 74:340.
- LS. Munoz-Price, K. Arheart , P. Nordmann, et al. Eighteen years of experience with *Acinetobacter baumannii* in a tertiary care hospital. *Crit Care Med* (2013); 41:2733.
- P. Mugnier, L. Poirel, M. Pitout, P. Nordmann, 2008. Carbapenem- resistant and OXA- 23-producing *Acinetobacter* isolates in the United Arab Emirates . *Clin. Microbiol. Infect.* (2008) 14, L 1879-882.
- S. Al-Obeid, L. Jabri, M. Al-Agamy, A. Al-Omari, A. Shibl. Epidemiology of extensive drug resistant *Acinetobacter baumannii* (XDRAB) at security forces hospital (SFH) in Kingdom of Saudi Arabia (KSA). *J Chemother* (2015);27:156-62.
- WS. Leung,CM. Chu, KY. Tsang , et al. Fulminant community-acquired *Acinetobacter baumannii* pneumonia as a distinct clinical syndrome. *Chest* (2006); 129:102.
- LG. Cordes , EW. Brink , PJ. Checko. et al. A cluster of *Acinetobacter* Pneumonia in foundry workers. *Ann Intern Med* (1981): 95:688.
- JT. Wang , LC. McDonald , SC. Chang , Community - acquired *Acinetobacter baumannii* bacteremia in adult patients in Taiwan. *J Clin Microbiol* 2002;40:1526.
- M. Federico , E. Ruiz, S. Mercedes , T. Eva , C. Esther , R. and Antonio . Crystal structure of hcp from *Acinetobacter baumannii*: A component of the type VI secretion system . *PLoS One*,(2015) 16;10 :e 0129691.
- A.P. Tomaras , C.W. Dorsey , C. Mcqueary , L.A. Actis , Molecular basis of *Acinetobacter* virulence and pathogenicity. In: *Acinetobacter Molecular Microbiology*.(2008) .
- L. Lisa, M. and Trish , *Acinetobacter baumannii*: Epidemiology, antimicrobial resistance and treatment Options. *Clinical Infectious Diseases*(2008) ,46:1254–63.
- C. Beggs , K. Kerr , A. Snelling , P. Sleight , *Acinetobacter* spp. And the clinical environment. *Indoor Built Environ.*(2006) , 15, 19-24.
- S. Islahi , F. Ahmad , V. Khare , S. Yaqoob , P. Shukla , Y. Singh , Incidence and risk factors associated with *Acinetobacter* species infection in hospitalised patients in a tertiary care hospital in North-India. *J. Commun. Dis.*(2015) , 46, 10-12.
- J. Cisneros, 1. Rodrigucz-Bano, Nosocomial bacteremia due to *Acinetobacter baumannii* Epidemiology , clinical features and treatment . *Clin . Microbiol . Infect .* (2002) , R, 687-693.
- J. Garnacho-Montero , R. Amaya-Villar , C. Ferrández-Millón , A. Díaz - Martín , J.M. López-Sánchez, A. Gutiérrez-Pizarra, 2015. Optimum treatment strategies for carbapenem-resistant *Acinetobacter baumannii* bacteremia. *Expert Rev. Anti Infect. Ther*(2015) ., 1-9.
- A.Y. Peleg , H. Seifert , D.L. Paterson , *Acinetobacter baumannii* : emergence of a successful pathogen. *Clin. Microbiol. Rev*(2008) . 21, 538-582.
- ZA. Kanafani , N. Zahreddine , R. Tayyar , et al. Multi-drug resistant *Acinetobacter* Species : a seven-year experience from a tertiary care center in Lebanon. *Antimicrob Resist Infect Control* (2018); 7:9.
- SS. Jean , PR. Hsueh , High burden of antimicrobial resistance in Asia. *Int J Antimicrob Agents* (2011); 37:291.
- N. Teerawattanapong , P. Panich , D. Kulpokin , et al. A Systematic Review of the Burden of Multidrug – Resistant Healthcare - Associated Infections Among Intensive Care Unit Patients in South east Asia : The Rise of Multidrug - Resistant *Acinetobacter baumannii*. *Infect Control Hosp Epidemiol* (2018); 39:525.
- ZA. Qureshi, LE. Hittle ,JA. O'Hara , et al. Colistin-resistant *Acinetobacter baumannii*: beyond carbapenem resistance. *Clin Infect Dis* (2015); 60:1295.
- R. M. Abd El- Baky , S. M. Farhan , R. A. Ibrahim , K. M. Mahran , and H. F. Hetta , "Antimicrobial resistance pattern and molecular epidemiology of ESBL and MBL producing *Acinetobacter baumannii* isolated from hospitals in Minia, Egypt," *Alexandria Journal of Medicine*,(2020) vol. 56, no. 1, pp. 4–13.

- G. Laura, M. Egidia, D. Olivia, B. Codrina, T. Andra, L. Cătălina, and D. Carmen. Appropriate empirical and antibacterial therapy for severe infection with nonfermenters. *Romanian Journal of Oral Rehabilitation*, (2014) 6: 60-68.
- N. Karah, F. Khalid, S. N. Wai et al., "Molecular epidemiology and antimicrobial resistance features of *Acinetobacter baumannii* clinical isolates from Pakistan," *Annals of Clinical Microbiology and Antimicrobials*, (2020), vol. 19 no. 1, p. 2.
- PG. Higgins, C. Dammhayn, M. Hackel, H. Seifer. Global spread of carbapenem-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother* (2010); 65:233.
- A. Brown. *Microbiological Applications. Laboratory manual in general microbiology*. McGraw-Hill. New York. (2005).
- A. Limansky, M. Mussi, A. and Viale. Loss of a 29-kilodalton outer membrane protein in *Acinetobacter baumannii* is associated with imipenem resistance. *Journal of Clinical Microbiology*, (2002), 40: 4776–4778.
- RA. Moghnieh, ZA. Kanafani, HZ. Tabaja, et al. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. *Lancet Infect Dis* (2018): 18:e379.
- P. Higgins, H. Wisplinghoff, D. Stefanik, and H. Seifert. Selection of topoisomerase mutations and overexpression of *adeB* mRNA transcripts during an outbreak of *Acinetobacter baumannii*. *Journal of Antimicrobial Chemotherapy* (2004), 54:821–823.
- C. Smith, and E. Baker. Aminoglycoside antibiotic resistance by enzymatic deactivation. *Curr Drug Targets Infect Disord*, (2002) 2: 143–160.
- Y. Doi, and Y. Arakawa. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. *Clinical Infectious Diseases*, (2007), 45: 88-94.
- A. Ribera, J. Ruiz, and J. Vila. Presence of the Tet M determinant in a clinical isolate of *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy* (2003), 47:2310–2312.
- T. Velkov, R. Soon, P. Chong, J. Huang, M. Cooper, M. Azad, et al. Molecular basis for the increased polymyxin susceptibility of *Klebsiella pneumoniae* strains with under-acylated lipid A. *Innate Immunity* (2013), 19: 77-265.
- A. Farajzadeh Sheikh, M. Savari, E. Abbasi Montazeri, and S. Khoshnood. "Genotyping and molecular characterization of clinical *Acinetobacter baumannii* isolates from a single hospital in Southwestern Iran," *Pathogens and Global Health*, (2020) vol. 114, no. 5, pp. 251–261.
- H. Tahmasebi, S. Dehbashi, M. Jahantigh, and M. R. Arabestani. "Relationship between biofilm gene expression with antimicrobial resistance pattern and clinical specimen type based on sequence types (STs) of methicillin-resistant *S. aureus*," *Molecular Biology Reports*, (2020), vol. 47, no. 2, pp. 1309–1320.
- S. K. Yadav, R. Bhujel, P. Hamal, S. K. Mishra, S. Sharma, and J. B. Sherchand. "Burden of multidrug-resistant *Acinetobacter baumannii* infection in hospitalized patients in a tertiary care hospital of Nepal," *Infection and Drug Resistance*, (2020), vol. 13, pp. 725–732, 2020.
- H. Tahmasebi, S. Dehbashi, and M. R. Arabestani. "Co-harboring of *mcr-1* and β -lactamase genes in *Pseudomonas aeruginosa* by high-resolution melting curve analysis (HRMA): molecular typing of superbug strains in bloodstream infections (BSI)," *Infection, Genetics and Evolution*, (2020), vol. 85, p. 104518, 2020.
- J. Moffatt, M. Harper, P. and Harrison. P. Colistin resistance in *Acinetobacter baumannii* is mediated by complete loss of lipopolysaccharide production. *Antimicrobial Agents and Chemotherapy*, (2010), 54:4971–7.
- Z. Qureshi, L. Hittle, J. O'Hara, J. Rivera, A. Syed, R. Shields, et al. Colistin-resistant *Acinetobacter baumannii*: beyond carbapenem resistance. *Clinical Infectious Diseases*, (2015), 1:1295-303.